Propanc Health Group Corporation — Form 10-Q
Reporting period: Quarter and six months ended December 31, 2016 (fiscal second quarter). The interim financial statements are unaudited. The filing identifies the registrant as Propanc Health Group Corporation, with Australian subsidiary Propanc Pty Ltd.
Business context
The company is a development-stage biotechnology business pursuing PRP, a preclinical pro-enzyme cancer-treatment candidate. It reported no revenue, had no products available for sale, and had not begun clinical trials. Its stated focus includes pancreatic, ovarian and colorectal cancers.
Financial performance and position
| Metric | Three months ended Dec. 31, 2016 | Six months ended Dec. 31, 2016 | Prior-year comparable |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $1.909 million | $3.083 million | $1.144 million / $2.151 million |
| Net loss | $3.761 million | $4.863 million | $3.562 million / $4.401 million |
| Operating cash used | Not provided for quarter | $1.005 million | $1.488 million |
- Six-month R&D expense was $328,399 versus $296,277; administration expense was $2.740 million versus $1.845 million. No meaningful revenue-based margin can be calculated.
- Cash was $42,918 at December 31, down from $121,070 at June 30. Total assets were $135,838; current liabilities were $3.976 million. The company reported a $3.854 million working-capital deficit and $3.841 million stockholders’ deficit.
- Current liabilities included $1.824 million of convertible notes and accrued interest, net, $1.100 million of embedded conversion-option liabilities, and $19,543 of warrant derivative liabilities. Director/officer loans of $53,258 were past due and in default; the filing says they bear no interest.
- Six-month financing cash flow was $959,285, mainly from $495,000 of convertible-note proceeds and $464,285 from warrant exercises. Cash declined by $78,152 over the period.
- Common shares outstanding increased from 728.6 million at June 30 to 867.3 million at December 31; 914.5 million were reported outstanding on February 14, 2017.
Changes versus prior comparable periods
- Six-month net loss increased by approximately $462,000, as operating expenses rose by approximately $932,000. Management attributed much of the administration increase to stock-based compensation and business-advisory consulting.
- Quarterly administration expense rose to $1.736 million from $996,129. Quarterly net loss increased to $3.761 million from $3.562 million.
- Cash used in operations improved to $1.005 million from $1.488 million, while financing cash inflow fell to $959,285 from $2.468 million.
- Six-month other expense included $1.727 million of interest expense and a $251,334 foreign-currency transaction loss. A $330,393 gain from changes in derivative fair value partly offset expenses; the comparable prior period recorded a $551,890 loss on derivative remeasurement.
Outlook, financing, risks and unusual items
- Going concern: Management said substantial doubt exists about the company’s ability to continue as a going concern. It stated cash was insufficient for obligations over the next 12 months and that substantial additional financing was required; there is no assurance financing will be available on acceptable terms.
- Debt and dilution: Several notes include variable-price conversion features, discounts to recent trading prices, default interest and potential penalties. The filing describes repeated debt conversions into common shares. These terms may create significant dilution. The principal Delafield debenture maturity had been extended to February 28, 2017.
- Development: PRP toxicology studies were ongoing; the company reported no adverse treatment-related findings to date and said the studies were intended to inform a potential UK clinical-trial starting dose. These are preliminary company-reported findings, not clinical evidence.
- Manufacturing commitment: The Q-Biologicals agreement anticipates $2.5 million to $5.0 million of payments over five years, with most spending expected in the first two years. A February 2017 subsequent-event disclosure reports payment of $62,079 toward a required prepayment.
- Other commitments and related parties: A five-year office lease is with a related party. The CEO received a $250,000 bonus that remained unpaid at period-end; the filing also discloses related-party employment, director advances and payments.
- Controls: Management concluded disclosure controls were ineffective and identified material weaknesses, including no audit committee financial expert, insufficient technical accounting expertise for complex debt/equity transactions, and inadequate segregation of duties.
- Subsequent events: The company disclosed a January 2017 Eagle Equities financing agreement and additional January conversions of debt into shares. It gave no revenue or earnings guidance.
Important facts for investors to verify
- Whether the company secured sufficient financing to meet near-term obligations and fund development, and the status of maturities, defaults and other debt terms.
- The updated share count, conversion activity, warrant status and potential dilution from variable-price convertible instruments.
- Progress and results of PRP toxicology, manufacturing readiness, clinical-trial plans and related spending commitments.
- Whether material weaknesses in financial reporting controls have been remediated.
- Patent status, particularly issuance of the allowed U.S. application and outcomes of pending applications.